The objective of this study was to investigate the predictive power of a high-sensitivity cardiac troponin I (hs-cTnI) assay for cardiovascular events and mortality in a large population of older community dwellers.
The measurement of cardiac troponins in blood is central in the diagnosis of acute coronary syndromes. The 99th percentile upper reference limits of these biomarkers are key elements of the Third Universal Definition of Myocardial Infarction (MI) 6 (1 ) . Cardiac troponins are increased in serum not only due to acute myocardial injuries, but also in noncardiac conditions such as pulmonary embolism, sepsis, chronic renal failure, ischemic stroke, and vigorous exercise (2 ) . The high-sensitivity cardiac troponin I (hs-cTnI) assays recently introduced allow for the measurement of cTnI in almost all healthy individuals (3 ) . The increased sensitivity of the assays also should allow for the earlier detection of myocardial injury in patients with acute MI as well as the identification of patients at risk of major adverse cardiac events and premature deaths. Cardiac troponins were shown to have additional value beyond the traditional risk factors for prediction of mortality, heart failure, and cardiovascular events in community-based cohorts. cTnT was measured in most of these studies (4 -6 ) , whereas there are fewer studies on cTnI (3, 7 ) .
The objectives of the present study of a large cohort of older community-dwelling individuals were to assess the additional prognostic value of hs-cTnI for major adverse cardiac events and mortality above traditional risk factors.
Methods

PARTICIPANTS/STUDY DESIGN
The Age, Gene/Environment Susceptibility-Reykjavik Study (AGES-Reykjavik) cohort is a community-based prospective study and has been described earlier (8 ) . Physical, physiological, and questionnaire examinations were conducted at 3 visits for each individual. An extensive data collection of various biological aspects and medical history, as well as recording of lifestyle factors, was performed. The first wave of the AGES-Reykjavik study was conducted during the years 2002-2006. The 5764 individuals included in the AGES-Reykjavik study were born between 1907 and 1935 and were selected randomly from the 11549 survivors of the Reykjavik Study cohort, which was initiated in 1967 by the Icelandic Heart Association (9 ) . The aim of the original study was to investigate prospectively risk factors for cardiovascular disease (CVD) in the Icelandic population. A total of 5706 individuals gave informed consent for access to hospital records and 5691 had valid hs-cTnI results and were included in this study. The AGES-Reykjavik study was approved by the National Bioethics Committee in Iceland, which acts as the Institutional Review Board for the Icelandic Heart Association (approval number VSN-00-063), by the National Institute on Aging Intramural Institutional Review Board, and the Data Protection Authority in Iceland. Informed consent was obtained from all study participants.
BIOCHEMICAL ANALYSIS, BLOOD SAMPLING/BASELINE EXAMINATION Blood samples were drawn after overnight fasting and centrifuged within 2 h at room temperature. The serum samples were divided into aliquots and immediately frozen and stored at Ϫ80°C. The serum samples were shipped on dry ice to Uppsala in Sweden before analysis.
In the AGES-Reykjavik study, lipids, creatinine, high-sensitive C-reactive protein (CRP), and glucose were analyzed in serum by use of a Hitachi 912 analyzer (Roche Diagnostics) with reagents from Roche Diagnostics and following the manufacturer's instructions. cTnI was measured using the cTnI assay from Abbott Diagnostics, ARCHITECT STAT high-sensitivity troponin. The limit of detection was reported to be 1.2 ng/L. A 10% CV was reported at a concentration of 8 ng/L and a 20% CV at 2 ng/L, as confirmed in a recent study (10 ) . Concentrations lower than the detection limit were assigned the value 1.2 ng/L. The 99th percentile concentrations of healthy men and women as indicated by the manufacturer were 34.2 and 15.6 ng/L, respectively. In the SWISCH (Sweden Women and Men and Ischemic Heart Disease) cohort of healthy Scandinavian individuals the 99th percentile concentrations were found to be 24.2 ng/L (men) and 15.2 ng/L (women) (11 ) .
Height and weight were measured, and body mass index (BMI) (kg/m 2 ) was calculated. Diabetes mellitus was defined as a fasting plasma glucose Ͼ126 mg/dL (Ͼ7.0 mmol/L) or self-reported history of diabetes or the use of insulin or oral glucose-lowering drugs. Hypertension was defined as current hypertension with resting blood pressure Ͼ140/90 mmHg as the mean value of 2 consecutive blood pressure measurements with a mercury sphygmomanometer and a large cuff, or treatment with antihypertensive drugs. Smoking status was defined as nonsmoker, previous smoker, or current smoker and obtained from a questionnaire. Previous CVD was defined as history of myocardial infarction, coronary heart disease (CHD), stroke, percutaneous transluminal coronary angioplasty (PTCA), or coronary artery bypass grafting (CABG) derived from hospital records, MI according to electrocardiogram, and bypass surgery determined from questionnaire, all occurring before entry to AGES-Reykjavik.
OUTCOMES/FOLLOW-UP EVALUATION
The outcomes in this study included: all-cause death, incident CHD, and incident CVD. Information on allcause death was recorded from a complete adjudicated registry of deaths available from the national mortality register of Iceland. Incident CHD was defined as MI, coronary revascularization by either CABG surgery or PTCA intervention according to hospital records, or death from CHD in participants with no previous history of CVDs [International Classification of Diseases, Tenth Revision (ICD-10) codes I21-I25].
Incident CVD was defined as CHD and stroke according to hospital records (ICD-10 codes I21-I25 and I610 -639) or death from CVD in participants with no previous history of CVDs.
Follow-up of all-cause death, incident CHD, and incident CVD was until December 31, 2013. Follow-up time was calculated as the number of days between baseline and death/event or end of follow-up, whichever happened first. The median follow-up for all-cause death was 8.9 years (interquartile ranges 6.6 -9.9 years). The median follow-up for incident CVD was 8.2 years (interquartile ranges 3.8 -9.6 years) and for incident CHD 8.4 years (interquartile ranges 4.1-9.6 years).
STATISTICAL ANALYSIS
Descriptive data are presented as percentages or median and interquartile ranges (25th-75th percentiles) or mean and SD. Specific quartiles of hs-cTnI were calculated. We tested the proportional hazard assumption for the hs-cTnI I variable. This was done both formally, using a test of interaction of the hs-cTnI variable with log(time), and visually, by inspecting scaled Shoenfeld residuals as a function of time.
Highly skewed variables (hs-cTnI, CRP, triglycerides, and creatinine) were logarithmically transformed to normalize the distribution. The nonparametric Mann-Whitney U-test was used for comparison between 2 groups and the Kruskal-Wallis test was used to compare baseline characteristics and outcomes across the different quartiles of hs-cTnI. P-values for trend were estimated by 2 analysis. The Pearson correlation coefficient was used to evaluate the relation between hs-cTnI concentrations and age.
Survival by quartiles of hs-cTnI was estimated by Kaplan-Meier survival analysis.
The relationships of hs-cTnI to death from all causes, incident CVD, and incident CHD were investigated separately for men and women after dividing the whole group into hs-cTnI quartiles with the use of Cox proportional-hazards regression in 2 models. These models elaborated separately for men and women were adjusted for established risk factors for CVD as follows: model a, adjusted for age; model b, adjusted for variable in model a plus diabetes, BMI, hypertension medication, systolic blood pressure, smoking, log CRP, log creatinine, cholesterol, HDL, log triglycerides, and statin medication.
The optimal cutpoints of hs-TnI for predicting all cause death and cardiovascular event were determined from the Youden index.
Predictive ability of the models with and without hs-cTnI were quantified by estimating the area under the receiver operating characteristic (ROC) curve (AUC) and by the net reclassification improvement (NRI) using log(hs-cTnI) with the variables as in model b. The AUC was estimated using the R-package timeROC (12 ) and the NRI was estimated using the R-package nricens.
A P value Ͻ0.05 was considered statistically significant.
Statistica for Windows v. 12.0 (Statsoft Inc.), MedCalc v 12.7 (MedCalc Software), STATA (StataCorp. 2011. Stata Statistical Software: Release 12) and R were used for the statistical analyses.
Results
BASELINE CHARACTERISTICS
The concentration of hs-cTnI was measured in 5691 individuals in the AGES-Reykjavik cohort; 2416 men, mean age 77 years (SD, 5.7 years) and 3275 women, mean age 77 years (SD, 6 years) collected during the years 2002-2006 (see Table 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol62/issue4).
Concentrations of hs-cTnI at or above the limit of detection of the assay were observed in 5682 patients (99.9%). The distribution of hs-cTnI concentrations by sex is shown in Fig. 1 , with higher values in men. The median concentration of hs-cTnI was 6.3 ng/L (interquartile range, 4.4 -10.5 ng/L) in the whole cohort. hs-cTnI concentrations were significantly higher in men than in women (P Ͻ 0.001). In men the median concentration was 8.4 ng/L (5.6 -14.2 ng/L) and in women 5.3 ng/L (3.8 -8.1 ng/L). hs-cTnI concentrations correlated significantly with age (r ϭ 0.32, P Ͻ 0.001) in the whole cohort (see online Supplementary Fig. 1 ) and in men (r ϭ 0.30 P Ͻ 0.001) and women (r ϭ 0.36, P Ͻ 0.001). Linear relationships between hs-cTnI concentrations and age were seen in both sexes irrespective of a history of previous CVD. For men the linear regression relationship was log 10 (y) ϭ Ϫ0.5497 ϩ 0.02005x, and for women the equation was log 10 (y) ϭ Ϫ0.6558 ϩ 0.01867x, where y was hs-cTnI and x was age in years. A total of 310 (12.8%) men had hs-cTnI concentrations above the 99th percentile (24.2 ng/L for men) and 296 (9%) women had hs-cTnI concentrations above the 99th percentile (15.2 ng/L for women). After elimination of individuals with previous cardiovascular events, diabetes mellitus, medication for hypertension, statin medication, and serum creatinine Ͼ1.3 mg/dL (115 mol/L), 70 (2.9%) men and 148 (4.5%) women had concentrations above the respective 99th percentiles THE RELATION OF hs-cTnI TO BASELINE VARIABLES, CVD RISK
FACTORS, AND OUTCOME
As summarized in online Supplementary Table 1 , significant sex differences were seen for most baseline variables. Notably, 39% of men and 21% of women had previous CVD, P Ͻ 0.001. The prevalence of diabetes mellitus was higher among men (16.5%) than women (11.2%), P Ͻ 0.001. More than 60% were on treatment with antihypertensive drugs, but with no difference between sexes. Deaths or incidences of CHD and CVD were all higher among men than among women. All-cause death 
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during the follow-up period was 48% in men as opposed to 37% in women, P Ͻ 0.001. Incidences of CVD vs CHD during this period were 18% vs 16% or 14% vs 12% for men and women, respectively, P Ͻ 0.001.
Online Supplementary Table 2 shows baseline variables relative to sex and quartiles of hs-cTnI. Major sex differences were seen in that results from women comprised 80% of the results of quartile 1 and only 36% of the results of quartile 4, P Ͻ 0.001. For most other variables we saw increased concentrations or proportions with increasing quartiles of hs-cTnI with the exceptions of total and HDL cholesterol in both sexes and triglycerides in men.
The numbers of individuals who suffered all-cause death and incidence of CVD and CHD per quartile of hs-cTnI are shown in Table 1 and separated by sex. The number of adverse events increased significantly in both men and women by increasing quartiles. Thus, when we compared the first with the second quartiles we found that all-cause death was increased almost 2-fold, i.e., from 20%-22% to more than 35%. No significant differences in proportions of all-cause death at the different quartiles of hs-cTnI were seen between the sexes, whereas the incidences of CVDs and CHD were higher among men, P Ͻ 0.001. A more detailed analysis of the relationship between all-cause death and hs-cTnI is shown in Fig.  2. Fig. 2 shows a very consistent linear association of hs-cTnI with all-cause death in men and women, with a 4-fold increase in all-cause death between the lowest and highest values for hs-cTnI. Similarly, the incidences of CVD and CHD increased linearly with increasing hs-cTnI concentrations (see online Supplementary Figs.  2 and 3) .
Adjusted hazard ratios (HRs) for age and sex in the whole cohort are presented in Table 2 . Adjusted HRs for all-cause death, incident cardiovascular events, and incident CHD were 2.31, 2.52, and 2.8 respectively. Ad-justed HRs for age were 2.27 for all-cause death, 2.53 for incident cardiovascular events, and 2.88 for incident coronary heart events for men in the highest quartile of hs-cTnI (Ͼ10.6 ng/L) (see online Supplementary Table  3a ). Similar results were seen in women (see online Supplementary Table 3b ). By Cox proportional hazard models adjusting for traditional risk factors including age, diabetes, BMI, hypertension medication, systolic blood pressure, smoking, log CRP, log creatinine, cholesterol, HDL cholesterol, log triglycerides, and statin medication, the HRs remained increased and highly significant over quartiles 2-4 in the whole cohort and separately in both men and women. A violation of the proportional hazard assumption was not detected. There was a strong and graded association between concentrations of hs-cTnI and all cause death, incidence of CVDs and CHDs. After adjustment for age, sex, diabetes, BMI, hy- Table 4 ). As shown in Fig. 3 by cumulative incidence graphs there were significant linear relationships over time between all-cause death (Fig. 3A) , incidence of CVD (Fig. 3B) , and incidence of CHD ( Fig. 3C ) and hs-cTnI quartiles. Similar Figs. based on sex-specific quartiles are shown in online Supplementary Fig. 4 , a-c. The interaction terms of sex on the associations of hs-cTnI with all 3 outcomes were not significant.
ROC ANALYSIS OF hs-cTnI
The c-index for the prediction of mortality, incidence of CVD and CHDs, was not significantly different between men and women. Table 3 shows the AUC with the inclusion of a number of risk factors and the increment in the AUC by the inclusion of hs-cTnI in the model. As can be seen there were significant increments in the AUCs of both all-cause death and incidences of CVD and CHD by adding hs-cTnI to the model for men and of all-cause death for women. However, a significant increase in the predictive ability of hs-cTnl beyond the use of traditional and novel risk factors was observed for incidence of CVD and CHD as measured by the net reclassification improvement in both men and women. The optimal cutpoints of hs-TnI for predicting allcause death and CVDs were 8.8 ng/L vs 7.0 ng/L or 9.4 ng/L vs 5.8 ng/L for men and women, respectively (see online Supplementary Fig. 5, a and b) .
Discussion
This report appears to be the first study of the predictive power of hs-cTnI assay (Abbott Diagnostics) in a large and older community-based population. The hs-cTnI assay used in this study measures very low concentrations and virtually all studied individuals (Ͼ99%) had concentrations above the level of detection. Four important conclusions were drawn from the study. First was the finding that hs-cTnI concentrations even within the reference interval, below the 99th percentile limits, were predictive of adverse events as to mortality and incidence in CVD. Second, the predicted rates of mortality and major adverse cardiac events increased with increasing concentrations of hs-cTnI. Third, there was a strong association of hs-cTnI with age. The concentrations increased linearly by age up to the age of 98 years in both men and women irrespective of any history of CVD. Fourth, hs-cTnI offered incremental predictive power over traditional risk factors for prediction of CHD and CVD.
The analytical sensitivity of cTnI assays has increased substantially over the last decade, with very few previous assays actually being able to accurately define the 99th percentile of a healthy population (13 ) . In this study we show that the median concentrations of hs-cTnI in a community-based older population is as low as onefourth to one-third of the 99th percentile of 25 ng/L and that the fourth quartile starts at the concentration of about 10 ng/L. In a previous study on a large cohort of children (14 ) the median concentrations using the same hs-cTnI assay were about half those found in our cohort. We speculate, therefore, that cTnI might leak out from older myocardial cells more readily than in younger persons. This finding was clearly supported by the progressive increase in cTnI with age, irrespective of sex and history of myocardial disease. A positive relation of hs-cTnI with age was previously found using the Beckman Coulter hs-cTnI prototype assay (15 ) and also the highsensitivity cTnT assay (16 ) ; however, with the hs-cTnI Beckman Coulter assay no sex differences were seen as opposed to the findings with the cTnT assay. This discrepancy is not readily explained, but there has been further evidence for the presence of sex differences recently (17 ) . Thus it seems safe to assume both sex and age differences in circulating concentrations of cardiac troponins, which should be taken into consideration when defining limits such as the 99th percentile.
Several previous studies have shown that cardiac troponins have powerful predictive value for adverse cardiovascular events and death (4, 5, 7, 18 -22 ) . The extraordinary findings in this large study on older individuals were the facts that strong associations to death and cardiovascular events were seen already at concentrations within reference intervals and increased linearly from these low to high concentrations of hs-cTnI. Thus, the HRs for adverse events in individuals having hs-cTnI concentrations in the second quartile, which started close to the median concentrations of presumably healthy individuals, were significantly higher than the HRs of those with concentrations in the first quartile. The HRs increased even further for individuals in the third and fourth quartiles. The exciting question is whether these relationships reflect genetics or pathophysiological pro- cesses or a combination of both. One author was involved in a previous study on 70-year-old men [ULSAM (the Uppsala Longitudinal Study of Adult Men) cohort], in which strong associations were found between slightly higher cTnI concentrations and adverse events even among the healthy individuals (23 ) . This finding was interpreted to reflect subclinical myocardial disease. In the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) cohort of 70-year-old men and women, hs-cTnI concentrations were independently predictive of death in those who had cTnI concentrations in the upper quartile (3 ). However, further stratification was not possible owing to the low frequency of events and therefore the associations to adverse outcome in the lower quartiles could not be determined.
One limitation of the current study is that only white indviduals were studied. However, in a similar study utilizing the hs-cTnT assay, deFilippi et al. (19 ) concluded that HRs did not depend on ethnicity, which may support the generalizability of our study. Thus, the employment of hs-cTn assays reveals the powerful prediction of adverse outcomes that is associated with very low concentrations and concentrations below reference intervals for these biomarkers.
In a recent report from the Nord-Trøndelag Health Study (HUNT) study (22 ) , a large, general population study, the prognostic value of hs-cTnI (also measured with the Abbott hs-cTnI assay) was stronger in women than in men. In the thorough examination of the AGES-Reykjavik cohort we could not discern any such differences. The reasons for this discrepancy are not quite clear but may be related to the large differences in age, because the mean age of the HUNT population was 50 years as compared to 77 years of the AGES-Reykjavik population. Our findings in the AGES cohort of no sex differences in the prognostic impact of hs-cTnI are similar to findings in the PIVUS cohort (24 ) . One speculation was that the results and discrepancies were biased by lower event rates in women with low hs-cTnI as compared to men. We also found much higher optimal cutpoints for the prediction of death and CVD in the AGES cohort as compared to the cutpoints found in the HUNT study. Again, this fact that may be related to the large differences in age between the 2 studies.
In conclusion, in our study of older individuals, hs-cTnI as measured by the Abbott assay was highly predictive of death and major adverse cardiac events and these events were predicted at blood concentrations far below the discrimination limit of the diagnosis of acute events of MI, i.e., the 99th percentiles and equally in both sexes. These findings show that the measurements of hs-cTnI, in addition to being used as a diagnostic means for acute myocardial injury, can be used to monitor and risk assess individuals for death and/or incidence of major adverse cardiac events. These data support previous findings that the measurements of hs-cTnI may be used for primary prevention of heart disease and should form the basis for future prospective clinical trials for determining whether measuring hs-cTnI can be applied in the prevention of CVD.
